Optimization of Cyclodextrin Loaded Lornoxicam Fast Dissolving Tablets Using Box- Behnken Design
Pharmaceutical Science-Pharmaceutics
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.5.P16-32Keywords:
Lornoxicam, HPβ Cyclodextrin, Box- Behnken factorial design, Dependent variables, Independent variablesAbstract
The present investigation was undertaken in the design and evaluation of fast dissolving tablets of the Non-Steroidal antiinflammatory drug Lornoxicam. Lornoxicam is an orally bio available oxicam derivative with anti inflammatory, antipyretic and analgesic properties upon oral administration. The main aim of this study is to prepare mouth dissolving tablets of hydroxyl propyl ß cyclodextrin loaded lornoxicam by Box-Behnken design. The main objective is to enhance the solubility, palatability of Lornoxicam by using cyclodextrin as a complexing agent and optimize the formulation by using Box-Behnken design.The inclusion complexes of Lornoxicam were prepared by physical mixture and solvent evaporation method by using drug and HP ß cyclodextrin in various ratios (1:1 and 1:2). Dissolution study was carried out for the 2 ratios of kneading method and solvent evaporation method. 1:1 ratio of solvent evaporation method was selected for the optimization by Box-Behnken design. The selected inclusion complexes were then utilized for the preparation of tablets by direct compression. The independent variables are lactose, sodium starch glycolate and crospovidone. The dependent factors studied were wetting time, in vitro disintegration, in vivo disintegration and in vitro dissolution. Optimized Formulae were prepared and evaluated for in vitro dissolution characteristics, in vitro disintegration time, wetting time, and their physico-mechanical properties. The predicted formula formulated with the Box-Behnken statistical design consisted of lactose, sodium starchglycolate and crospovidone at the optimum levels of 30, 20 and 20 mg respectively which is considered as the best optimized formulation with good dissolution profile. The bioavailability has been increased from the optimized formulation. The formulation was evaluated for stability.From the research a taste masked mouth dissolving tablet formulation is selected to increase patient compliance with enhanced solubility, dissolution and stability.
References
Swati S, Sai Suma, Lalitha R, NavyaPrasanna S. Formulation and evaluation of glipizide fast dissolving tablets. J Pharm Sci Res. 2020;12(1):609-11.
Ashish P, Mishra P, Main p, Harsoliya MS, Agrawal S. A review on- recent advancement in the development of rapid disintegrating tablet. IJLPR. 2011;1:7-16.
Marwa H, Abdallah. Box-behnken design for development and optimization of acetazolamide microspheres. Int J Pharm Sci Drug Res. 2014;5(4):1228-39.
Madhuri TH, Ravi DH. Formulation and evaluation of fast dissolving tablet of lamotrigine. Int J Pharm Sci Drug Res. 2018;7(2):50-7. doi: 10.31638/IJPRS.V7.I2.00030.
Pavan KR, Prakash BM, Shailendra Singh K, Amarjit AS, Vivek BR, Nityanand SZ. Fast dissolving tablets of pioglitazone hydrochloride by use of VariousSuperdisintegrants. Int J Adv Res Biol Sci. 2013:74-9.
Kullich W, Klein G. AktuelRheumatol. 1992:128-32.
Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D. Pharmacokinetics of lornoxicam in man. Postgrad Med J. 1990;66;Suppl 4:66.1990; 22–27. PMID 2284217.
Buritova J, Besson JM. Dose-related anti-inflammatory/analgesic effects of lornoxicam: a spinal c-Fos protein study in the rat. Inflam Res. 1998;47(1):47.1998;18–25. doi: 10.1007/s000110050245, PMID 9495582.
Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996;51(4):639-57. doi: 10.2165/00003495-199651040-00008, PMID 8706598.
Pruss TP, Stroissnig H, Radhofer-Welte S, Wendtlandt W, Mehdi N, Takacs F, Fellier H. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J. 1990;66;Suppl 4:66.1990;18–21. PMID 2284216.
Zhang Y, Zhong D. SiD, GuoY, ChenX, et al. Br J Clin Pharmacol:59.2005; 14–17.
Turner P, Johnston A. Postgrad Med J:66.1990; 28–29.
Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J ClinPharmacol. 1996;49(4):305-8. doi: 10.1007/BF00226332, PMID 8857077.
Rao MT, Maha Lakshmi J, Srinivasa Rao Y. Formulation and characterization of indomethacin cyclodextrinloadedmouth dissolving films. Int. Curr j. J Adv Res. 2018; 8(15);15117:110.
Hannan PA, Khan JA, Khan A, Safiullah S. Oral dispersible system. A new approach in drug delivery system. Indian J Pharm Sci. 2016;78(1):2-7. doi: 10.4103/0250-474x.180244, PMID 27168675.
Singh B, Geetanjali Saini DNSharmaN, etal.Estimation of lornoxicam in tablet dosage form by UV spectrophotometric method. Int J Pharm Sci Drug Res. 2011;2(1):102-6.
Sahoo SK, Giri RK, Patil SV, et al. Development of ultraviolet spectrophotometric method for analysis ofLornoxicam in solid dosage forms. Trop J Pharm Res. 2012;11(2):269-73.
Amin AS, El-Henawee MM, Ragab GH, et al. Spectrophotometric determination of lornoxicam in pure and in pharmaceutical formulations using ion-associate complex formation. Int. j. adv. res. Chem Sci. 2014;1(6):1-9.
AtulBendale R, JigneshkumarMakwana J, SushilNarkhede P, et al. Analytical method development and validation protocol for lornoxicam in tablet dosage form. J Chem Pharm Res. 2011;3(2):258-63.
RaneVipul P, Jaiprakash N, et al. PatilKiran R. Stab Indicating LC Method Anal Lornoxicam Dosage Form.J. Chromatogr. A. 2009;2(1):9-10.
Chilate VC, Godbole MD, Sonaye HV, et al. To mask the bitter taste of rizatriptan benzoate and develop water dispersible tablets. Int J Curr Res Rev. 2017; 9;21:39-48.
Peppas NA, Gurney R, et al. Mechanism of solute release from porous hydrophilic polymers. Korsmeyer RW. Int J Pharm. 1983;15;22:35-9.
Costa P, Manuel JM, Lobo S. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-33. doi: 10.1016/s0928-0987(01)00095-1, PMID 11297896.
Gattani SG, moon RS. Formulation and evaluation of fast dissolving tablet containing vilazodonenanocrystals for solubility and dissolution enhancement using soluplus: in vitro-in vivo study. J Appl Pharm Sci. 2018; 8:045-54.
Vishal Dhiman, Gaurav Jain, VaibhavJagtap. Formulation and in-vitro evaluation of fast dissolving tablets of telmisartan. Int J Pharm Sci Drug Res. 2012;3:2159-64.
Liu HL, Lan Y, Cheng YC. Optimal production of sulphuric acid by Thiobacillusthiooxidans using response surface methodology. Process Biochem. 2004;39(12):1953-61. doi: 10.1016/j.procbio.2003.09.018.
Dasari N, Maruvajala V. Preparation and evaluation of fast dissolving tablets of pitavastatin by 32 full factorial design. Int J Appl Pharm. 2020;12(1):108-14. doi: 10.22159/ijap.2020v12i1.35678.
Yarraguntla SR, Sharmila M, et al.,Application of Box-Behnken Design for Formulation Parameters of Eslicarbazepine Tablets. ParavastuVenkata kamala Kumari. Int J Appl Pharm. 2021;83(3):575-83.
Soroush H, Ghorbani-Bidkorbeh F, Mortazavi SA, Mehramizi A. Formulation optimization and assessment of dexamethasone orally disintegrating tablets using Box-Behnken design. Iran J Pharm Res. 2018;17(4):1150-63. PMID 30568675.
Roy H, Nandi S, Pavani U, Lakshmi U, Reddy TS, Gayatri DVS. optimization and quakity by design approach for prioxicam fast dissolving tablet formulations using Box-Behnken design. Curr Drug Ther. 2020;15(2):152-65. doi: 10.2174/1574885514666190409102614.
Muthukumar S, Sankar C, Swetha K, Pradeepa R, et al. Formulation and evaluation of metronidazole benzoate loaded proniosomes for topical delivery. IJLPR.2022;12(1):55-66.
Rao MT. Vijayaratna J, Srinivasa Rao Y, etal.Development and validation of RP-HPLC method for the determination of itraconazole in bulk and capsule dosage form. Int J Pharm Sci Rev Res. 2015;31:221-5.
Sharma GN, kumar CHP, Shrivastava B, B. Kumar. Optimization and characterization of chitosan-based nanoparticles containing methylprednisolone using box-behnken design for the treatment of Crohn’s disease. Int J Appl Pharm. 2020;12(2):12-23. doi: 10.22159/ijap.2020v12i2.36462.
Roy H, Rahaman A. Box-Behnken design for optimization of formulation variables for fast dissolving tablet of Uradipil. Asian J Pharm. 2018;12(3):946-54.
Hong SaijieZM, Liu C, Pei Y. Application of Box-Behnken design in understanding the quality of genistein self-nanoemulsified drug delivery systems and optimizing its formulation. Int J Appl Pharm. 2009;14(6):642-9.37.
Samy AM, Ramadan AA, Abu El-EninASm, Mortagi YIM. Formulation and optimization of itraconazoleproniosomes using box behnken design. Int J Appl Pharm. 2018;10(2):41-51. doi: 10.22159/ijap.2018v10i2.23382.
Okhuelegbe S, Osayande EP. et al. optimization of disintegrant blends using Box- Behnken design in the formulation of fast disintegrating tablets of diclofenac sodium. Nig. J Pharm Sci. 2017;6(2):1-7.
Chettupalli AK, Rao PA, Kuchukuntla M, Bakshi V. Development and optimization of aripiprazole ODT by using box- behnken design. Res J Pharm Technol. 2020;13(12):6195-201. doi: 10.5958/0974-360X.2020.01080.X.
Published
How to Cite
Issue
Section
Copyright (c) 2022 M.Trinadha Rao, M.Yamini, Ch.V.S. Phanindra, P.N. Mallikarjun, P.V. Kamalakumari, Y. Srinivasa Rao
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
